"Expanding Access to Heart-Healthy Weight Loss Drugs: The Wegovy and Semaglutide Revolution"

The weight loss drug Wegovy, previously approved for weight management, has now been approved for heart health as well. However, its $1,350 monthly cost has led to reluctance from some employers and health plans to provide coverage. While some insurers may consider covering the treatment in the future, questions remain about its long-term use and cost effectiveness. The drug's approval highlights its potential downstream health benefits for severe conditions caused by obesity, but concerns about its cost and long-term use persist among insurers and employers.